Novaliq’s dry eye disease therapy receives US FDA approval
Pharmaceutical Technology
JUNE 9, 2023
CyclASol is topical anti-inflammatory and immunomodulating ophthalmic drug solution containing 0.1% Novaliq medical science and regulatory affairs vice-president Sonja Krösser stated: “We are proud that the FDA approved VEVYE.
Let's personalize your content